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Abstract 
p53 is one of the most intensively studied tumor suppressor genes. Recent cancer genomic 
analyses using next-generation sequencing technique revealed that mutations of the p53 
gene are still the most common alteration observed in the majority of human cancers. 
Alterations in the p53 gene are clustered in its DNA-binding domain, implying that 
transactivation of target genes is pivotal mechanism of tumor suppressive function of p53, 
and therefore identification and functional analysis of p53-targets are of importance in 
cancer research. A number of p53 target genes have been previously isolated. However, the 
full picture of the p53 downstream pathway still remains to be elucidated. To identify novel 
p53 targets, we here performed transcriptome and proteome analysis, and I further 
analyzed the function of the newly identified genes.  
 To identify novel p53 targets, we conducted cDNA microarray analysis and mass 
spectrometry analysis using mRNAs and whole cell lysates, respectively, isolated from 
HCT116p53+/+ and HCT116 p53-/- cells that were treated with 2 µg/ml of ADR. RNA and 
protein were collected at 0, 12, 24, 48, and 72 h after ADR treatment. We obtained 
expression data of total 22,275 genes from the transcriptome analysis and 3,363 proteins 
from the proteome analysis. After applying the screening criteria, I identified 166 genes and 
91 proteins including 16 and 6 known p53-downstream targets, respectively. Among the 
novel candidates, I selected EPSIN3 from transcriptome analysis and CYSTATIN C from 
proteome analysis. To confirm the result of cDNA microarray and mass spectrometry 
analysis, I performed qPCR analysis and western blot analysis. I found that EPSIN3 and 
CYSTATIN C were remarkably induced by ADR in a p53-dependent manner. Next, I 
surveyed for p53 binding sequence (p53BS) within their genetic loci and identified two 
p53BSs in the promoter region of the EPSIN3 gene and one p53BS in the first intron in the 
CYSTATIN C gene. The DNA fragments containing p53BSs were amplified and subcloned 
upstream of the minimal promoter in pGL4.24 vector (pGL4.24/p53BS). The result of 
reporter assay revealed that U373MG cells transfected with pGL4.24/p53BS showed 
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increased luciferase activity only in the presence of plasmid expressing wild-type p53. To 
verify whether p53 could directly bind to p53BSs, I performed ChIP assay using U373MG 
cells that were infected with either Ad-p53 or Ad-LacZ. After precipitation by an anti-p53 
antibody, DNA fragments harboring BSs were quantified by qPCR. As a result, p53 
specifically bound to p53BS2 (EPSIN3) and p53BS (CYSTATIN C) in cells infected with 
Ad-p53.  
 Epsins are accessory proteins implicated in clathrin-mediated endocytosis by 
binding ubiquitin moieties on the cytoplasmic part of membrane proteins. To date, the 
functions of EPSIN3 in both normal and cancer cells are largely unknown. To explore the 
role of EPSIN3 in the growth of cancer cells, I performed colony formation assay using three 
cancer cell lines: H1299, HCT116, and U373MG. As a result, colony formation was 
significantly impaired in HCT116 and U373MG cells which had been transfected with 
EPSIN3 expressing plasmid compared with mock. I subsequently analyzed cell viability by 
ATP measurement assay and found that EPSIN3 knockdown inhibited the ADR-induced 
growth suppression to the same degree as cells treated with sip53. I further examined the 
impact of EPSIN3 on ADR-induced apoptosis. Interestingly, knockdown of EPSIN3 in 
ADR-treated HCT116 cells increased pro-caspase 3 and reduced cleaved caspase3, 
indicating the regulation of apoptosis by EPSIN3. 
 Cystatins are reversible, tight binding inhibitors against C1 cysteine proteases, 
which exert various physiological functions. Among the family, CYSTATIN C has been the 
most intensively studied and shown to inhibits cathepsin L, a lysosomal cysteine protease, 
that is highly expressed in various cancer cells and is involved in cancer development and 
progression. First, I analyzed cell viability by ATP measure assay and found that 
CYSTATIN C knockdown inhibited the ADR-induced growth suppression to the same degree 
as cells treated with sip53. Next, I found that knockdown of CYSTATIN C in ADR-treated 
HCT116 cells increased pro-caspase 3 and reduced cleaved caspase 3, indicating the 
regulation of apoptosis by CYSTATIN C. When HEK293T cells were transfected with 
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plasmid expressing CYSTATIN C, cathepsin L activity was markedly decreased compared 
with mock-transfected cells. Then I measured cathepsin L activity in HCT116 p53-/-, p53+/+ 
or CYSTATIN C-silenced p53+/+ cells that were treated with ADR. As a result, cathepsin L 
activity was significantly reduced in HCT116 p53+/+ cells after ADR treatment, while ADR 
treatment increased cathepsin L activity in p53-/- cells or CYSTATIN C-silenced p53+/+ cells. 
These results indicated that p53-CYSTATIN C pathway regulates cathepsin L activity.  
 I identified EPSIN3 and CYSTATIN C as novel p53 targets using transcriptome 
and proteome analysis, respectively. Both genes promote apoptosis of cancer cells in 
regulation of p53.  
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Introduction 
p53 is one of the most intensively studied tumor suppressor genes [1-3]. p53 is a 
short-lived transcription factor and its intracellular level is maintained to be low 
through proteasomal degradation, which is mainly mediated by E3 ligase activity of 
murine double minute 2 (MDM2) [4, 5]. p53 transactivates MDM2 expression through 
the promoters of MDM gene and constitutes a negative feedback loop, resulting in 
maintaining itself at appropriate level (Figure 1). When cells are exposed to cellular 
stresses such as DNA damage, hypoxia, or oncogene activation, ataxia telangiectasia 
mutated (ATM) are activated. ATM inhibits E3 ligase functions of MDM2 through 
phosphorylation of the catalytic domain of MDM2, and subsequently prevents p53 from 
ubiquitin-proteasomal degradation [6] (Figure 2). Moreover, a number of modifications 
within p53 itself simultaneously occur. Within 30 min after DNA damage, Ser15 of p53 is 
phosphorylated by ATM followed by subsequent phosphorylation of Thr18 by CK1 and 
Ser20 by CHK2 [7-9]. These modifications negatively affect the p53-MDM2 interaction, 
resulting in p53 stabilization.  
 Thus, p53 activated by cellular stresses induces transcription of hundreds of its 
target genes and exerts various functions such as cell cycle arrest, senescence, apoptosis, 
and posttranscriptional modification [10-12] (Figure 3). Mutations of p53 gene has been 
found in approximately 50% of human cancers [13], and recent cancer genomic analyses 
using next-generation sequencing technique further revealed that mutations of the p53 
gene are still the most common alteration observed in the majority of human cancers 
[14]. According to International Agency for Research on Cancer TP53 database, 73% of 
alterations in p53 gene are missense mutations and 98% of those are clustered in its 
DNA-binding domain through which the p53 protein binds to specific DNA element [15, 
16]. Kato and co-workers examined transcriptional activities of 2,314 missense 
mutant-p53 using site-directed mutagenesis and showed that 64% of mutations in the 
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DNA-binding domain of p53 result in loss of its transcriptional activity [17]. These 
observations imply that transactivation of target genes is pivotal mechanism of tumor 
suppressive function of p53, and therefore identification and functional analysis of 
p53-targets are of importance in cancer research. Our group have previously identified 
a number of p53-target genes. In 2000, using a yeast enhancer trap system [18], I 
screened human genomic sequences which activates transcription in p53-dependent 
manner, and isolated p53AIP1 as a novel p53-target gene involved in apoptosis [19]. In 
the same year, using differential display method [20], we isolated p53R2, which plays a 
role in DNA repair under the regulation of p53 [21]. To comprehensively screen 
p53-targets, we performed cDNA microarray using U373MG cells (glioblastoma with 
p53 mutation) infected with adenovirus designed to express p53 [22] and identified 
p53RDL1 as an effecter of p53-mediated apoptosis. Using the same method, we 
subsequently identified three novel p53-targets: XEDAR, PADI4, and ISCU, which are 
involved in anoikis, histone modification, and iron regulation, respectively [12, 23-25]. 
In spite of the researchers' efforts, full picture of the p53 downstream pathway still 
remains to be elucidated and recent exhaustive methods have suggested that numerous 
unknown targets exist. To identify novel p53-targets, we here performed transcriptome 
and proteome analysis and further analyzed the function of novel p53 targets. 
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Materials and Methods 
cDNA microarray 
Gene expression analysis was performed using SurePrint G3 Human GE 8 × 60K 
microarray (Agilent, Santa Clara, CA, USA) according to the manufacturer's protocol. 
Briefly, HCT116 p53+/+ or HCT116 p53-/- cells were treated with ADR and incubated at 
37°C until the time of harvest. Total RNA was isolated from the cells using standard 
protocols. Each RNA sample was labeled and hybridized to array slides.  
 
Mass spectrometric analysis.  
Cells were lysed in [8M urea, 50 mM HEPES-NaOH, pH = 8.0] and reduced with 10 mM 
tris(2-carboxyethyl)phosphine (Sigma-Aldrich, St. Louis, MO, USA)) at 37°C for 30 min, 
followed by alkylation with 50 mM iodoacetamide (Sigma-Aldrich) at 25°C in dark for 
45 min. Proteins were digested with Immobilized trypsin (Thermo Scientific, Waltham, 
MA, USA) at 37°C for 6 hours. The resulting peptides were desalted by Oasis HLB 
µ-elution plate (Waters , Milford, MA, USA) and analyzed by LTQ-Orbitrap-Velos mass 
spectrometer (Thermo Scientific) combined with UltiMate 3000 RSLC nano-flow HPLC 
system (Thermo Scientific). The MS/MS spectra were searched against Homo sapiens 
protein sequence database in SwissProt using Proteome Discoverer 1.4 software 
(Thermo Scientific), in which false discovery rate of 1% was set for both peptide and 
protein identification filters. Differential peptide quantification analysis (label-free 
quantification analysis) for 10 samples was performed on Expressionist Server platform 
(Genedata AG, Swiss) as described previously [26].  
 
Cell culture and transfection. 
Human embryonic kidney cells HEK293T were obtained from Riken Cell Bank (Ibaraki, 
Japan). Human cancer cell lines U373MG (astrocytoma), H1299 (non-small cell lung 
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cancer), HCT116 (colorectal adenocarcinoma), and HBL100 (breast carcinoma) were 
purchased from American Type Culture Collection. Huma n mammary epithelial cells 
MCF10A p53+/+ or MCF10A p53-/- were purchased from Sigma Aldrich. HBC4 (breast 
carcinoma) was gifted from T. Yamori (Japanese Foundation for Cancer Research, Tokyo, 
Japan). HCT116 p53+/+ and HCT116 p53-/- cell lines were gifts from B. Vogelstein (Johns 
Hopkins University, Baltimore, MD, USA). HEK293T and U373MG cells were 
transfected with plasmids using Fugene6 (Promega, Madison, WI, USA), and 
Lipofectamin LTX (Invitrogen, Carlsbad, CA, USA), respectively. Small interfering RNA 
(siRNA) oligonucleotides, commercially synthesized by Sigma Genosys (Woollands, TX, 
USA), were transfected with Lipofectamine RNAiMAX reagent (Invitrogen). Sequences 
of siRNA oligonucleotides are shown in Table 1.  
 
Cell treatments 
We generated and purified replication-deficient recombinant viruses expressing p53 
(Ad-p53) or LacZ (Ad-LacZ) as described previously [19]. U373MG (p53-mutant) and 
H1299 (p53-deficient) cells were infected with viral solutions at various amounts of 
multiplicity of infection (MOI) and incubated at 37°C until the time of harvest. For 
treatment with genotoxic stress, cells were incubated with 2 µg/ml of adriamycin (ADR) 
for 2 h. As oxidative stress, cells were continuously incubated in medium with 200mM 
Hydrogen peroxide (H2O2) (Wako, Osaka, Japan) at 37°C until the time of harvest.  
 
Quantitative real-time PCR. 
Total RNA was isolated from human cells and mouse tissues using RNeasy Plus Mini 
Kits (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. 
Complementary DNAs were synthesized using Super Script III reverse transcriptase 
(Invitrogen). Quantitative real-timePCR (qPCR) was conducted using SYBR Green 
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Master Mix on a Light Cycler 480 (Roche, Basel, Switzerland). Primer sequences are 
shown in Table 1. 
 
Western blot analysis   
To prepare whole cell extracts, cells were collected and lysed in chilled RIPA buffer (50 
mmol/L Tris-HCl at pH 8.0, 150 mmol/L NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 
and 1% NP40) containing 1 mM phenyl methylsulphonyl fluoride (PMSF), 0.1 mM DTT 
and 0.1% Calbiochem Protease Inhibitor Cocktail Set III, EDTA-Free (EMD Chemicals 
Inc., Merck KGaA, Darmstadt, Germany). Samples were sonicated for 15 min with a 
30-sec on/30-sec off cycle using Bioruptor UCD-200 (Cosmobio, Tokyo, Japan). After 
centrifugation at 16,000 × g for 15 min, supernatants were collected and boiled in SDS 
sample buffer (Biorad, Hercules, CA, USA). SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) was performed for each sample, and the proteins were then transferred to 
a nitrocellulose membrane (Hybond™ ECL™, Amersham, Piscataway, NJ, USA). 
Protein bands on western blots were visualized by ECL Western Blotting Detection 
Reagent (Amersham) or Immnobilon Western Chemiluminescent HRP Substrate 
(Merck Millipore, Darmstadt, Germany). 
 
Antibodies  
Anti-actin monoclonal antibody (AC15) and anti-EPSIN3 polyclonal antibody 
(HPA055546) were purchased from Sigma-Aldrich. Anti- CYSTATIN C monoclonal 
antibody (C27) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Anti-p21 monoclonal antibody (OP64) and anti-p53 monoclonal antibody (OP43) were 
purchased from Merck Millipore. Anti-caspase 3 monoclonal antibody (8G10) and 
anti-cleaved caspase 3 monoclonal antibody (5A1E) were purchased from Cell Signaling 
Technology (Beverly, MA, USA).  
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Gene reporter assay 
DNA fragments, including the potential p53-binding sequence were amplified and 
subcloned into the pGL4.24-promoter vector (Promega). Primers for amplification are 
shown in Table 1. Point mutations “T” were inserted at the 4th and the 14th nucleotide 
“C” and the 7th and the 17th nucleotide “G” of the potential p53-binding sequence by 
site-directed mutagenesis (Table 1). Reporter assays were performed using the Dual 
Luciferase assay system (Promega) as described previously [23].  
 
Chromatin immunoprecipitation assay.  
ChIP assay was performed using EZ-Magna ChIP G Chromatin Immunoprecipitation 
Kit (Merck Millipore) following the manufacturer’s protocol. In brief, U373MG cells 
infected with Ad-p53 or Ad-LacZ at an MOI of 10 were cross-linked with 1% 
formaldehyde for 10 min, washed with PBS, and lysed in nuclear lysis buffer. The lysate 
was then sonicated using Bioruptor UCD-200 (CosmoBio) to shear DNA to 
approximately 200-1000 bp. Supernatant from 1 × 106 cells was used for each 
immunoprecipitation with anti-p53 antibody (OP140, Merck Millipore) or normal mouse 
IgG (sc-2025, Santa Cruz). Before immunoprecipitation, 2% of supernatant was 
removed as “input”. Column-purified DNA was quantified by qPCR. Primer sequences 
are shown in Table 1. 
 
Cell proliferation and apoptosis analysis 
HCT116 cells were seeded on cell-culture dishes coated with polyethyleneimine and 
transfected with siRNAs. At 24 h after transfection, cells were transfered to ultra-low 
attachment plates (Corning, NY, USA). After another 24 h, cells were treated with 1 
µg/ml of ADR for 48 h. To assess cell viability, cells were subjected to ATP measurement 
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assay using Cell Titer-Glo Luminescent Viability Assay (Promega) according to the 
manufacturer's protocol. For the detection of apoptosis, cells treated as above were 
subjected to western blot analysis by using anti-pro-caspase 3 and cleaved caspase 3 
antibodies.  
 
Plasmid construction. 
The entire coding sequences of EPSIN 3 and CYSTATIN C cDNA were amplified by 
PCR using KOD-Plus DNA polymerase (Toyobo, Osaka, Japan), and inserted into the 
EcoRI and XhoI sites of pCAGGS vector. The constructs were confirmed by DNA 
sequence analysis. Primers used for amplification are shown in Table 1. 
 
Immunocytochemistry 
Adherent cells were fixed with 4% paraformaldehyde in PBS and permeabilized with 
0.2% Triton X-100 in PBS for 5 min at room temperature. The cells were then covered 
with blocking solution (3% BSA/PBS containing 0.2% Triton X-100) for 1 h at room 
temperature and incubated with rabbit anti-EPSIN 3 antibody (diluted 1:500) or mouse 
anti-p53 antibody (diluted 1:1000) in blocking solution overnight at 4 °C. Primary 
antibodies were stained with goat anti-rabbit or anti-mouse secondary antibodies 
conjugated to Alexa488 or Alexa594 (each diluted 1:2000) for 1h at room temperature, 
stained with DAPI and visualized with Fluoview FV1000 confocal microscope (Olympus, 
Tokyo, Japan). 
 
Knockout mouse 
p53-deficient mice were provided from RIKEN BioResource Center (Ibaraki, Japan) [27]. 
Genotypes were confirmed by PCR analysis. Frozen sperms of Epsin 3-/+ C57BL/6N mice 
were purchase from UC Davis Knockout Mouse Depository (vector design is shown in 
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Figure 23). After Epsin 3-/+ mice were obtained by in vitro fertilization, Epsin 3-/- mice 
were generated from male/female pairs of Epsin 3-/+ mice. The primer sequences are 
indicated in Table 1. All mice were maintained under specific pathogen-free conditions 
and were handled in accordance with the Guidelines for Animal Experiments of the 
Institute of Medical Science (University of Tokyo, Tokyo, Japan).  
 
Immnohistochemistry 
Sections of stomach of 6-week-old mice that were formalin-fixed and paraffin-embedded 
were subjected to immunohistochemistry. After deparaffinization with xylene, antigen 
was retrieved at 125°C for 30sec in DAKO Target Retrieval Solution (EDTA buffer, pH 
6.0). Intrinsic peroxidase and proteins were blocked. Anti- Epsin 3 antibody diluted to 
1/150 with DAKO Antibody Diluent was added to the samples and incubated for 1 h at 
370C and subsequently reacted with Envision Plus anti-rabbit IgG as a 2nd antibody for 
1 h at 370C. Substrate chromogen was added, and the specimens were counterstained 
with haematoxylin. 
 
Wound healing experiment 
A Full-thickness excisional wounds were created on the dorsum of Six-week-old Epsin 
3-/- or Epsin 3+/+ mice using a 5 mm diameter of biopsy punch (Kai Medical, Gifu, Japan). 
The wounds were photographed at day 0, 3, 5 and 7 and the area of wounds were 
calculated by Adobe PhotoShop CS3 (Adobe Systems, San Jose, USA) 
 
Survival and tumor development assay 
For survival analysis, 8 Epsin 3-/- and 14 Epsin 3+/+ mice at the age of 6 weeks were 
irradiated with 10 Gy of X-ray using X-ray irradiation system (MBR-1520R-3,Hitachi). 
Overall survival was defined as the days from irradiation to death from any cause. To 
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initiate tumor development, 19 Epsin 3-/- and 14 Epsin 3+/+ mice at the age of 6 weeks 
were irradiated with 4 Gy of X-ray at day 1, 8, 15, and 21. Tumor-free survival was 
defined as the days from irradiation to appearance of tumor or death from any cause.   
 
Cathepsin L activity assay 
Cathepsin L activity assay was performed using Cathepsin L Activity Assay Kit 
(Promokine, Heidelberg, Germany) following the manufacturer’s protocol. Briefly, HEK 
293T cells transfected with CYSTATIN C expression plasmid or mock plasmid were 
collected at 36 h after transfection. HCT116 p53/-/- , HCT116 p53+/+, or CYSTATIN 
C-silenced HCT116 p53+/+ cells treated with 2 µg/ml of ADR for 2 h were collected 48 h 
after treatment. The cells were lysed with lysis buffer provided in the kit. Protein 
concentration of each lysate was measured by Pierce BCA Protein Asssay Kit (Thermo 
Fisher Scientific) and diluted to 0.60 µg/µl. After adding DTT for a final concentration of 
4 mM and fluorescent substrate to the lysates, samples were incubated for 1 h at 37°C, 
and fluorescence was measured at ex 405 / em 500 in ARVO X3 plate reader (Perkin 
Elmer). 
 
Database analysis 
EPSIN 3 and CYSTATIN C expression level in clinical samples were obtained from the 
TCGA project via data portal on 15 May 2015 [28]. p53 mutation status in cancer 
tissues were collected from the TCGA website, and the expression levels of CYSTATIN 
C in three sample categories: normal tissues, tumors with wild-type p53, and tumors 
with mutant p53 were compared using the Mann-Whitney U test. Clinical data was also 
downloaded from the TCGA website and survival analysis was performed using 
log-rank test stratified by expression level of CYSTATIN C in tumor (above or below the 
median expression level of the cohort).  
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Results 
Screening of p53 downstream targets 
To identify novel p53-targets, we conducted cDNA microarray analysis and mass 
spectrometry analysis using mRNAs and whole cell lysates, respectively, isolated from 
HCT116p53+/+ and HCT116 p53-/- cells that were treated with 2 µg/ml of ADR (Figure 3). 
RNA and protein were collected at 0, 12, 24, and 48 (protein was additionally collected 
at 72 h), after ADR treatment. Gene expression analysis was performed using SurePrint 
G3 Human GE 8 × 60K microarray. Protein expression was determined by LC-MS/MS 
analysis. We obtained expression data of total 22,275 genes from the transcriptome 
analysis and 3,363 proteins from the proteome analysis. To screen candidates that were 
induced by ADR damage in p53-dependent manner, I applied the following criteria;   
1) The intensity in HCT116 p53+/+ cells is 10-fold higher in transcriptome analysis 
and 3-fold higher in proteome analysis than that in HCT116 p53-/- cells at 2 or 
more time points,  
2) In HCT116 p53+/+ cells, the intensities are 3-fold higher than that at 0 hours at 2 
or more time points,  
3) The maximum intensity in HCT116 p53+/+ cells is 2-fold higher than that in 
HCT116 p53-/- cells  
After this screening, I identified 166 genes and 91 proteins including 16 and 6 known 
p53-downstream targets, respectively. Among the novel candidates, I selected EPSIN 3 
(EPN3) from transcriptome analysis and CYSTATIN C (CST3) from proteome analysis 
because they were markedly induced.  
 
EPSIN 3 and CYSTATIN C are induced by DNA damage and p53 
To confirm the result of cDNA microarray and mass spectrometry analysis, I performed 
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quantitative real-time PCR (qPCR) analysis. I found that EPSIN 3 and CYSTATIN C  
mRNA were remarkably induced by ADR only in HCT116 p53+/+ cells (Figure 4, 8).  In 
accordance with the qPCR results, EPSIN 3 and CYSTATIN C  proteins were induced 
by ADR in p53+/+ cells (Figure 4, 8). CYSTATIN C mRNA was also induced by hydrogen 
peroxide in HCT116 p53+/+ cells (Figure 9). I also confirmed the induction of EPSIN 3 
mRNA and CYSTATIN C mRNA by ADR treatment in MCF10A p53+/+ normal breast 
epithelial cells but not in MCF10A p53-/- cells and (Figure 5, 10). I further verified that 
CYSTATIN C mRNAs were induced by ADR damage in HBC4 and HBL100 breast 
adenocarcinoma cell lines harboring wild-type p53, while CYSTATIN C induction was 
impaired by silencing of p53 (Figure 11). 
To further evaluate the induction of EPSIN 3 and CYSTATIN C by p53, U373MG and 
H1299 cells were infected with Ad-p53 or Ad-LacZ. I found that mRNA and protein of 
both candidates were induced in cells infected with Ad-p53, indicating the regulation of 
EPSIN 3 and CYSTATIN C by p53 (Figure 6, 12). Then I measured the expression of 
both genes in p53+/+ or p53-/- mice that were irradiated with 10 Gy of X-ray. At 24 h after 
irradiation, RNA purified from thymus were subjected to qPCR analysis. As a result, 
Epsin 3 and Cystatin C mRNA were increased by X-ray irradiation in the thymus of 
p53+/+ mice but not in the thymus of p53-/- mice (Figure 7, 13). These results clearly 
demonstrated the regulation of EPSIN 3 and CYSTATIN C by p53 in vitro and in vivo.  
 
EPSIN 3 and CYSTATIN C is a direct target of p53 
To investigate whether EPSIN 3 and CYSTATIN C are direct targets of p53, I surveyed 
for p53-binding sequence (p53BS) [16] within their genetic loci and identified two 
potential binding sequences (p53BS1 and p53BS2) in the promoter region of EPSIN 3 
gene and one p53BS in first intron in CYSTATIN C gene (Figure 14). A 449-bases DNA 
fragment containing p53BS1 and p53BS2 of EPSIN 3 (p53BS1+2) and 263-bases DNA 
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fragment containing p53BS of CYSTATIN C (p53BS) were amplified and subcloned 
upstream of the minimal promoter in pGL4.24 vector (pGL4.24/p53BS). The result of 
reporter assay revealed that U373MG cells transfected with pGL4.24/p53BS1+2 or 
pGL4.24/p53BS showed increased luciferase activity only in the presence of plasmid 
expressing wild-type p53 (Figure 15). However, base substitutions in the p53BS2 of 
EPSIN 3 or p53BS of CYSTATIN C (pGL4.24/BSmut) completely diminished the 
enhancement of luciferase activity. These findings suggested that p53 transactivates 
EPSIN 3 and CYSTATIN C through p53BS2 and p53BS, respectively. Since I generated 
Epsin 3-deficient mice, I also surveyed p53-binding sequence in mouse Epsin 3 gene and 
found two potential binding sequences: mp53BS1 in promoter region, which was 
corresponding to human p53BS2, and mp53BS2 in the first intron. Of note, subsequent 
reporter assay revealed that luciferase activity was remarkably elevated in the cells 
transfected with pGL4.24/mp53BS2 rather than pGL4.24/mp53BS1 (Figure 16).   
 To verify whether p53 could directly bind to p53BSs, I performed ChIP assay 
using U373MG cells that were infected with either Ad-p53 or Ad-LacZ. After 
precipitation by an anti-p53 antibody, DNA fragments harboring p53BSs were 
quantified by qPCR. As a result, p53 specifically bound to p53BS2 (EPSIN 3) and p53BS 
(CYSTATIN C) in cells infected with Ad-p53 (Figure 17). Taken together, I concluded 
that EPSIN 3 and CYSTATIN C are direct p53-targets.  
 
Functional analysis of EPSIN 3 
Epsins are accessory proteins implicated in clathrin-mediated endocytosis by binding 
ubiquitin moieties on the cytoplasmic part of membrane proteins. To date, three family 
members (EPSIN 1-3) have been identified in vertebrates. EPSIN 1 and EPSIN 2 are 
ubiquitously expressed in most type of tissues and were shown to be involved in the 
internalization of membrane proteins such as Notch ligands, eepithelial sodium channel, 
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epithelial growth factor receptor (EGFR), protease-activating receptor 1 and vascular 
endothelial growth factor 2 (VEGFR2) [29-33]. Targeted deletion of both EPSIN 1 and 
EPSIN 2 results in embryonic lethality due to defective vascular phenotype, suggesting 
that EPSIN 1 and EPSIN 2 play important and complementary roles in developmental 
stage [34]. In cancer tissues, there are growing evidences indicating up-regulation of  
EPSIN 1 and EPSIN 2 and their oncogenic implication [35]. EPSIN 1 promotes tumor 
angiogenesis regulating VEGF signaling pathway through internalization of VRGFR2 
[33] and also endocytosis of Notch and Notch ligand. Besides internalization of 
membrane proteins, N-terminal ENTH domain of epsin activates GTPases, Rac1 and Arf6, 
through inhibition of RalBP1, a GTPase-activating protein (GAP), and subsequently results in actin 
remodeling and migration of cancer cells [33, 35]. As a novel function of epsins, a recent 
report showed that EPSIN 1 and EPSIN 2 interact with dishevelled2, a effecter protein 
of Wnt signaling, and prohibits its degradation, resulting in potentiating Wnt signaling 
and ensuing cancer progression [36].  
In contrast to EPSIN 1 and EPSIN 2, the distribution of EPSIN 3 in mammalian body is 
highly limited. EPSIN 3 protein was shown to be expressed in the wounded 
keratinocytes and gastric parietal cells [37, 38]. Since EPSIN 3 share the major domains 
with the other family members, it has been expected that EPSIN 3 has also similar 
functions. However, the roles of this gene in both normal and cancer cells are largely 
unknown. Thus, I investigated the function of EPSIN 3 as a p53-target.    
 
EPSIN 3 is localized in inner surface of plasma membrane 
To examine the subcellular localization of EPSIN 3, I performed immunocytochemistry 
using ADR-treated HCT116 p53+/+ and p53-/- cells and HEK293T cells transfected with 
EPSIN 3 expressing plasmid. I found EPSIN 3 in the inner surface of plasma membrane 
of ADR-treated HCT116 p53+/+ cells in which p53 were activated. On the other hand, 
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EPSIN 3 was rarely expressed in HCT116 p53+/+ without ADR treatment or HCT116 
p53-/- cells, consistent with the results of qPCR and western blot analysis (Figure 18). 
Ectopically expressed EPSIN 3 was also localized in inner surface of plasma membrane  
similar with EPSIN 1, suggesting that EPSIN 3 also interacts with membrane proteins 
(Figure 19).  
 
Regulation of cancer cell growth and apoptosis by EPSIN 3 
To explore the role of EPSIN 3 in the growth of cancer cells, I performed colony 
formation assay using three cancer cell lines: H1299, HCT116, and U373MG. As a 
results, colony formation was significantly impaired in HCT116 and U373MG cells 
which had been transfected with EPSIN 3 expressing plasmid compared with mock 
(Figure 20). Next, I designed four siRNAs (siEPN3-a-d) and found that both siEPN3-b 
and siEPN3-d effectively suppressed EPSIN 3 mRNA and protein (Figure 21). At the 
same time, I confirmed the specific protein bands of EPSIN 3. I subsequently analyzed 
cell viability by ATP measurement assay and found that EPSIN 3 knockdown inhibited 
the ADR-induced growth suppression to the same degree as cells treated with sip53 
(Figure 22A). I further examined the impact of EPSIN 3 on ADR-induced apoptosis. 
Interestingly, knockdown of EPSIN 3 in ADR-treated HCT116 cells increased 
pro-caspase 3 and reduced cleaved caspase3, indicating the regulation of apoptosis by 
EPSIN 3 (Figure 22B). 
 
Epsin 3-deficient mice show no phenotypic alterations 
To investigate in vivo function of Epsin 3, I investigated Epsin 3- deficient mice. Frozen 
sperm purchased from knockout mouse project (KOMP) repository at UC Davis was 
recovered by using conventional in vitro fertilization and embryo transfer methods. 
Genotyping of new born mice were conducted by using specific primer set (Figure  23). 
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Firstly, I evaluated Epsin 3 mRNA level of thymus tissue from 10 Gy of X-ray irradiated 
mice and confirmed not only knockout of the gene but induction by DNA damage in 
Epsin 3-wild-type mice (Figure 24A) . I next validated Epsin 3-knockout in protein level 
by western blot and immunohistochemistry using mouse stomach tissues (Figure 
24B,C), in which protein expression of Epsin 3 is relatively higher than other tissues 
[38]. Unlike the previous study, where Epsin 3 was localized in gastric parietal cells [38],  
Epsin 3 was found in the whole of fundic glands in my immunohistochemistry study 
probably due to the specificity of the antibody. Epsin 3-deficient mice were born at the 
expected Mendelian frequency, had no obvious physiological defects and had no 
difference in biochemical analysis of blood samples compared to Epsin 3-wild-type mice.   
 In general, high dose X-ray irradiation causes depletion of bone marrow cells 
and subsequent death during 12-20 days after irradiation, while p53-deficient mice are 
resistant to the lethal myelosuppression, indicating a crucial role of p53 in genotoxic 
stress-mediated apoptosis of bone marrow cells [39]. Because I had demonstrated 
regulation of cell apoptosis through p53-EPSIN 3 pathway in vitro, I tested whether  
Epsin 3 deficiency affects survival of X-ray irradiated mice. As a result, I found no 
significant difference between Epsin 3-wild-type and deficient mice in overall survival 
(Figure 25A). Next, I irradiated 6-weeks-old Epsin 3-wild-type or deficient mice with 4 
Gy of X-ray for 4 times (once per week) to evaluate differences in tumor incidence. 
However, tumor free survival did not differ between the two groups (Figure 25B). 
 Because a previous report showed that EPSIN 3 was localized specifically to 
migrating keratinocytes in cutaneous wounds [37], I hypothesize that EPSIN 3 is 
involved in wound healing process. To test this hypothesis, I performed wound healing 
experiment using Epsin 3-deficient or wild-type mice. Contrary to my expectations, 
wound healing rates of Epsin 3-deficient mice were not different from those of Epsin 
3-wild-type mice (Figure 26).  
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Down-regulation of EPSIN 3 in colorectal cancer 
To address the involvement of EPSIN 3 in human carcinogenesis, I investigated the 
expression of EPSIN 3 by using RNA sequence data of colorectal adenocarcinoma 
tissues released from the TCGA database [28]. Notably, expression of EPSIN 3 was 
significantly decreased in colorectal adenocarcinoma tissues compared with the 
corresponding normal tissues (Figure 27). Taken together, the present findings would 
suggest the important role of EPSIN 3 in colorectal carcinogenesis.  
 
Functional analysis of CYSTATIN C 
Cystatins are reversible, tight binding inhibitors against C1 cysteine proteases, which 
exert various physiological functions. Cystatin family members are categorized into 
three groups. Type 1 cystatins, also called stefins, are intracellular proteins which are 
present in most cells (cystatin A and B). Type 2 cystatins are secreted proteins found in 
most body fluids (CYSTATIN C, D, E⁄M, F, G, H, S, SA and SN). Type 3, also referred to 
as kininogens, are large multifunctional glycoproteins in body fluids, which  work as 
acute phase proteins [40]. In the immune system, cystatins generally elicits 
immunosuppressive responses. Fetuin-A, a type 3 cystatin, down-regulates the 
pro-inflammatory cytokines and prevents excessive inflammation in wounded tissues 
[41, 42]. Type 2 cystatins inhibit autolysis of matrix metalloproteinases, which is an 
essential process for intact remodeling of the extracellular matrix [43]. CYSTATIN C, 
the most abundant type 2 cystatin, inhibits cathepsin L and S that are involved in 
antigen processing in antigen-presenting cells, resulting in suppression of MHC class II 
molecules-mediated immune responses [44].  
 Expression of cystatins in cancer tissues differs among the various cystatins, 
cancer types and clinical stages. For example, stefin A and B exhibited reduced 
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expression in breast cancer, malignant meningioma, and glioblastoma [45-49], while 
they were elevated in small cell or non-small cell lung cancer tissues [50, 51].  An 
inverse correlation between CYSTATIN C level and clinical stage of glioma and prostate 
cancer was demonstrated [52], while high serum CYSTATIN C level was shown to be 
associated with poor prognosis of colorectal cancer and melanoma [53, 54]. Thus the 
regulation of cystains and their roles in human carcinogenesis still remain unknown. I 
had identified CYSTATIN C as a p53-target and analyzed here the involvement of 
p53-CYSTATIN C pathway in cancer.  
 
Regulation of cancer cell growth and apoptosis by CYSTATIN C 
To explore the role of CYSTATIN C in the growth of cancer cells, I designed two siRNAs 
(siCystC-a and siCystC-b) and found that both siCystC-a and siCystC-b effectively 
suppressed CYSTATIN C mRNA and protein (Figure 28). I subsequently analyzed cell 
viability by ATP measurement assay and found that CYSTATIN C knockdown inhibited 
the ADR-induced growth suppression to the same degree as cells treated with sip53  
(Figure 29A). Next, I examined the impact of CYSTATIN C on ADR-induced apoptosis. 
Interestingly, knockdown of CYSTATIN C in ADR-treated HCT116 cells increased 
pro-caspase 3 and reduced cleaved caspase 3, indicating the regulation of apoptosis by 
CYSTATIN C (Figure 29B).  
 
Regulation of cathepsin L by p53-CYSTATIN C pathway 
The lysosomal cysteine protease, cathepsin L, is an inhibitory target of CYSTATIN C 
[55]. Cathepsin L is highly expressed in various cancer cells and is involved in cancer 
development and progression [56, 57]. When HEK293T cells were transfected with 
plasmid expressing CYSTATIN C, cathepsin L activity was markedly decreased 
compared with mock-transfected cells (Figure 30A). Then I measured cathepsin L 
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activity in HCT116 p53+/+ or p53-/- cells that were treated with ADR. As a result, 
cathepsin L activity was significantly reduced in HCT116 p53+/+ cells after ADR 
treatment, while ADR treatment increased cathepsin L activity in p53-/- cells (Figure 
30B). I further evaluated cathepsin L activity in HCT116 p53+/+ that were treated with 
ADR at 24 h after transfection with siRNAs. As expected, p53 and CYSTATIN C 
knockdown resulted in increased activity of cathepsin L compared with control cells 
(Figure 30C). This result indicates that p53-CYSTATIN C pathway negatively regulates 
cathepsin L activity. 
 
Regulation of CYSTATIN C by p53 in vivo 
To explore the role of CYSTATIN C in human carcinogenesis, I investigated the 
expression of CYSTATIN C by using RNA sequence data of colorectal adenocarcinoma 
and breast adenocarcinoma tissues released from the TCGA database [28]. Notably, 
expression of CYSTATIN C was significantly decreased in both colorectal and breast 
adenocarcinoma tissues compared with the corresponding normal tissues (Figure 31). 
Moreover, CYSTATIN C expression in breast cancer tissues with p53 mutation was 
significantly lower than those without p53 mutation. Since CYSTATIN C expression 
was not reduced in breast cancer tissues with wild-type p53 compared to the 
corresponding normal tissues, p53 inactivation is likely to be the major cause of 
CYSTATIN C suppression in breast cancer tissues. I further assessed the impact of 
CYSTATIN C expression and p53 mutation on clinical outcome by using the TCGA 
dataset. Concordant with the previous report [58, 59], breast cancer patients without 
p53 mutation indicated better prognosis (Figure 32A). I also found that breast cancer 
patients with high CYSTATIN C expression exhibited significantly longer survival than 
those with low CYSTATIN C expression (Figure 32B). Moreover, multivariate analysis 
revealed that lower CYSTATIN C expression was an independent predictor of poor 
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prognosis in the patients with breast cancer (Table 2). Taken together, the results 
suggest that the p53-CYSTATIN C pathway plays an important role in the development 
and progression of human cancers. 
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Discussion  
Here I identified EPSIN 3 and CYSTATIN C as novel p53 targets. Although several 
lines of evidence suggest that EPSIN 1 and 2 are implicated in carcinogenesis, I showed 
EPSIN 3 was induced by p53 and exerts tumor suppressive functions. Since epsin 
family members share structural similarities each other, it is difficult to explain 
functional diversities observed among them. However, my results of immunoblotting 
may provide some insights. There were two protein bands at approximately 75kDa 
(full-length size) and 40 kDa in the lane of whole cell lysate from HEK293T cells 
introduced with EPSIN 3, in contrast to that of EPSIN 1 in which only single band of 
full-length size was observed (Figure 19). This result indicates that EPSIN 3, not 
EPSIN 1, is cleaved into two parts. Further research is needed to elucidate the role of 
cleaved EPSIN 3. 
 In my analysis, I demonstrated that EPSIN 3 mediates apoptotic signaling in 
cancer cells. DNA damage provokes intrinsic apoptotic signaling cascade, in which a 
number of genes including known p53-targets form a complicated network [60]. Notably, 
knockdown of EPSIN 3 abrogated cleavage of caspase 3 as the same degree as 
p53-knockdown, suggesting that EPSIN 3 is involved in a common step in p53-caspase 3 
axis. Among the known p53-targets involved in apoptosis, EPSIN 3 may play a pivotal 
role as one of the p53-induced apoptosis mediator.  
 Consistent with previous a report, my Epsin 3-deficient mice showed no 
pathological phenotypes. I speculated that it was because Epsin 3 expression level was 
extremely low in most of organs. Therefore, I irradiated mice to induce Epsin 3 
expression in wild-type mice. However, there were no difference in survival and tumor 
development between Epsin 3-deficient and wild-type mice. This result could be 
partially explained by the fact that p53-binding sequence is not conserved between 
human and mice (Figure 16). Although human EPSIN 3 is induced in many types of cell 
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lines, mouse Epsin 3 was induced only in thymus. Therefore, regulatory mechanism as 
well as their physiological function would be different between human and mouse 
EPSIN 3.  
 CYSTATIN C is ubiquitously expressed in most organs and distributed in all 
body fluid compartments. Various physiological and pathological functions of 
CYSTATIN C have been reported such as apoptosis induction in neural cells, restriction 
of antigen presentation in antigen-presenting cells, and extracellular matrix remodeling 
[61]. In addition, several lines of evidence suggest the roles of CYSTATIN C in 
carcinogenesis. Down-regulation of CYSTATIN C in cancer tissues has repeatedly been 
reported [51, 62, 63], but the results are still controversial [64, 65]. So, I revealed that 
CYSTATIN C is a p53-downstream target which is involved in p53-induced apoptosis. 
The expression analysis using the TCGA database revealed that CYSTATIN C 
expression was negatively associated with p53 mutation in cancer tissues. Since p53 is 
frequently mutated in cancer tissues, down-regulation of CYSTATIN C in cancer tissues 
would mainly be caused by p53 inactivation.  
 I also showed that p53 negatively regulated cathepsin L activity in response to 
DNA damage. p53 mutations in cancer tissues are associated with aggressive features 
and poor prognosis [66-72], but the molecular mechanism whereby p53 regulates cancer 
progression is not yet fully elucidated. Cathepsin L is one of the physiologically 
essential enzymes implicated in the degradation of extracellular matrix, modulation of 
immune response, and tissue development [73]. In cancer cells, cathepsin L was 
up-regulated, and its secreted form was shown to degradate extracellular matrix and 
promote cancer cell invasion [56, 74]. In addition, activated cathepsin L interferes with 
apoptosis of cancer cells [75]. Secreted CYSTATIN C was shown to be internalized into 
cancer cells and reduce cathepsin activity [76], and ectopically expressed CYSTATIN C 
reduced the invasiveness of melanoma cells [77]. Since cathepsin L activity is related 
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with tumor development and progression, the present findings suggested that negative 
regulation of cathepsin L by CYSTATIN C may play a crucial role in the tumor 
suppressive function of p53. 
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Figure 1. MDM2 regulates p53 stability.  
(A) MDM2-p53 constitutes a negative feedback loop. Green ellipse indicates 
ubiquitilytion of p53 protein, leading to its degradation. (B) Cellular stresses induces ATM , 
a protein kinase, which phosphorylates MDM2 and p53 (yellow circles ), resulting in 
preventing interaction of MDM2 with p53.   
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Figure 2. Schematic of p53-mediated responses after cellular stresses. 
Various cellular stresses shown in the red box induce p53 activation. Activated p53 
binds to the region of target genes  thoμgh specific p53-binding sequence, and 
thereby transcription of the gene exerts tumor suppressive response shown in the 
blue box. 
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Figure 3. Schematic diagram of screening methodology of p53-inducible targets. 
HCT116 p53-/- or p53+/+ cells harvested at the indicated times after 2 μg/ml ADR treatment 
for 2 h were subjected to transcriptome and proteome analysis. The selection criteria in the 
blue box was used to extract p53-inducible targets from the Raw data.  Gene names of 
known p53-targets screened by each method were shown in the red boxes. 
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Figure 4. Induction of CYSTATIN C by DNA damage. 
qPCR analysis of EPSIN 3 in HCT116 p53-/- or p53+/+ cells harvested at the indicated 
times after 2 μg/ml ADR treatment for 2 h (upper). β-actin was used for the 
normalization of expression levels. Error bars represent S.D. (n = 3). HCT116 p53-/- or 
HCT116 p53+/+ cells were treated with 2 μg/ml ADR for 2 h. At the indicated times after 
the treatment, whole cell extracts were subjected to immunoblotting using anti-
CYSTATIN C, anti-p53, anti-p21, or anti-actin antibody (lower) 
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Figure 5. Induction of EPSIN 3 by DNA damage in mammalian cells 
qPCR analysis of EPSIN 3 in MCF10A p53-/- or p53+/+ cells harvested at the 
indicated times after 2 μg/ml ADR treatment for 2 h. β-actin was used for 
the normalization of expression levels. Error bars represent S.D. (n = 2).  
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Figure 6. Induction of EPSIN 3 by p53. 
(Upper) qPCR analysis of EPSIN 3 in U373MG (p53 mutant) and H1299 (p53 null) cells 
infected with adenovirus expressing p53 (Ad-p53) or LacZ (Ad-LacZ) at multiplicity of 
infection (MOI) of 10 or 20. β-actin was used for the normalization of expression levels. 
Error bars represent S.D. (n = 3). (lower) U373MG cells and H1299 were infected with Ad-
p53 or Ad-LacZ at MOI of 10 or 20. At 36 h after treatment, whole cell extracts were 
subjected to Western blot with anti-EPSIN 3, anti-p21, or anti-actin antibody 
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Figure 7. Induction of Epsin 3 by DNA damage in mouse tissues 
qPCR analysis of Epsin 3 expression in the thymus of X-ray-irradiated 
p53−/− or p53+/+ mice (10 Gy) (n=3 per group). β-actin was used for the 
normalization of expression levels. Mice were sacrificed 24 h after 
irradiation with 10 Gy of X-ray. 
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Figure 8. Induction of CYSTATIN C by DNA damage. 
qPCR analysis of CYSTATIN C in HCT116 p53-/- or p53+/+ cells harvested at the indicated times 
after 2 μg/ml ADR treatment for 2 h (upper). β-actin was used for the normalization of 
expression levels. Error bars represent S.D. (n = 3). HCT116 p53-/- or HCT116 p53+/+ cells 
were treated with 2 μg/ml ADR for 2 h. At the indicated times after the treatment, whole 
cell extracts were subjected to Western blot using anti-CYSTATIN C, anti-p53, anti-p21, or 
anti-actin antibody (lower) 
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Figure 9. Induction of CYSTATIN C by oxydative stress. 
HCT116 p53-/- or HCT116 p53+/+ cells were treated with 200mM H2O2. 
At the indicated times after treatment, qPCR analysis was performed. 
β-actin was used for the normalization of expression levels. Error bars 
represent S.D. (n = 3) 
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Figure 10. Induction of CYSTATIN C by DNA damage in normal mammalian cells 
and breast cancer cells 
qPCR analysis of CYSTATIN C in MCF10A p53-/- or p53+/+ cells harvested at the 
indicated times after 2 μg/ml of ADR treatment for 2 h. β-actin was used for the 
normalization of expression levels. Error bars represent S.D. (n = 3).  
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Figure 11. Induction of CYSTATIN C by DNA damage in breast cancer cells 
HBC4 and HBL100 cells were transfected with sip53, 24 h prior to treatment with ADR. 
siEGFP and no transfection (noTF) were used as controls. At 48 h after 2 μg/ml of ADR 
treatment, total RNA were subjected to qPCR. β-actin was used for the normalization of 
expression levels. Error bars represent S.D. (n = 3).  
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Figure 12. Induction of CYSTATIN C by p53. 
(Upper) qPCR analysis of CYSTATIN C in U373MG and H1299 cells infected with Ad-p53)or 
Ad-LacZ at MOI of 10 or 20. β-actin was used for the normalization of expression levels. 
Error bars represent S.D. (n = 3). (Lower) U373MG cells were infected with Ad-p53 or Ad-
LacZ at MOI of 10 or 20. At 36 h after treatment, whole cell extracts were subjected to 
immunoblotting with anti-CYSTATIN C, anti-p21, or anti-actin antibody 
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Figure 13. Induction of CYSTATIN C by DNA damage in mouse tissues 
qPCR analysis of cystatic C expression in the thymus of X-ray-irradiated 
p53−/− or p53+/+ mice (10 Gy) (n=3 per group). β-actin was used for the 
normalization of expression levels. Mice were sacrificed 24 h after 
irradiation with 10 Gy of X-ray. 
24h Thymus 
10 Gy 
p53-/- p53-/- 
p53+/+ p53+/+ qPCR 
46 
p53BS1 p53BS2 
EPSIN 3 
1kb 
p53BS 
CYSTATIN C 
1kb 
Consensus R R R C W W G Y Y Y R R R C W W G Y Y Y 
p53BS 1 A G G C A T G C T g G G G C g T G g T C 17/20 
p53BS 2 c t G C A A G T C a G G A C A g G T T T 16/20 
p53BS 1mut A G G T A T T C T g G G G T g T T g T C 
p53BS 2mut c t G T A A T T C a G G A T A g T T T T 
Consensus R R R C W W G Y Y Y R R R C W W G Y Y Y 
p53BS G A G C A T G C C T G A c C c T G C C T 18/20 
p53BSmut G A G T A T T C C T G A c T c T T C C T 
Figure 14. Genomic structure of EPSIN 3 and CYSTATIN C gene.  
The white boxes indicate the location of the potential p53-binding sequence (p53BS). 
Comparison of p53BS to the consensus p53-binding sequence. R, purine; W, A or T; Y, 
pyrimidine. Identical nucleotides to the consensus sequence are written in capital 
letters. The underlined cytosine and guanine were substituted for thymine to 
examine the specificity of the p53-binding sequence. 
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Figure15. p53 transactivates luciferase throμgh p53BSs   
Results of luciferase assay of the genomic fragment containing p53BSs with or without 
substitutions at p53BSs. Luciferase activity is indicated relative to the activity of mock vector 
with S.D. (n = 3). Mutant p53 represents plasmid expressing p53 with a missense mutation 
(R175H). 
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Figure 16. Genomic structure of mouse Epsin 3 gene and the results of reporter assay 
(A) The white boxes indicate the location of the potential p53-binding sequence (mp53BS). 
Comparison of mp53BS to the consensus p53-binding sequence. R, purine; W, A or T; Y, 
pyrimidine. Identical nucleotides to the consensus sequence are written in capital letters. 
(B) Results of luciferase assay of the genomic fragment containing. Luciferase activity is 
indicated relative to the activity of mock vector with S.D. (n = 3).  
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Figure 17. p53 directly binds to p53 binding sequences of EPSIN 3 and CYSTATIN C 
ChIP assay was performed using U373MG cells that were infected at an MOI of 10 
with Ad-p53 (lane 2-4) or Ad-LacZ (lane 1). DNA-protein complexes were 
immunoprecipitated with an anti-p53 antibody (lane 1 and 2) followed by qPCR 
analysis. Input chromatin represents a small portion (2%) of the sonicated 
chromatin before immunoprecipitation. Immunoprecipitates with an anti-IgG 
antibody (lane 3) or in the absence of an antibody (lane 4) were used as negative 
controls. Error bars represent S.D. (n = 3).  
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Figure 18. Endogenous EPSIN 3 is localized in inner surface of plasma membrane. 
After 2 μg/ml of ADR treatment for 2 h or no treatment, HCT116 p53-/- or p53+/+ cells 
were incubated for 48 h. Adherent cells were  fixed with 4% paraformaldehyde in PBS 
and permeabilized with 0.2% Triton X-100 in PBS for 5 min at room temperature. 
EPSIN 3 (green) and p53 (red) were visualized using specific primary antibodies and 
fluorescein-conjμgated 2nd antibodies. Nucleus was stained with DAPI (blue).  
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Figure 19. Exogenous epsin1 and 3 localized in inner surface of plasma membrane. 
Thirty-six hours after transfection with HA-tagged-EPSIN 3 expression  vector, HA-tagged 
–epsin1 expression vector, or mock vector, HEK293T cells were collected and the whole 
cell extracts were subjected to westernblotting and immunocytochemistry analysis using 
anti-HA antibody.   
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Figure. 20. Ectopically expressed EPSIN 3  suppressed cancer cell growth 
H1299, HCT116 and U373MG cells transfected with EPSIN 3 expressing plasmid  or 
mock vector were cultured in the media containing 0.8, 0.5 and 0.5 mg/ml of 
geneticin , respectively, for 2-3 weeks. Error bars represent S.D. (n = 3). P- value was 
calculated by Student's t-test.  
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Figure 21. Knockdown of EPSIN 3 expression by siRNA.  
We designed four small interference RNAs (siRNAs): siIEPN3-a-d. HCT116 cells were 
transfected with each siRNA, 24 h prior to treatment with ADR. siEGFP was used as a 
control. At 48 h after treatment, total RNA and whole cell extracts were subjected to 
qPCR and Western blot analysis, respectively. Red arrows indicate the protein bands of 
EPSIN 3. β-actin was used for normalization of expression levels in qRT-PCR analysis. Error 
bars represent S.D. (n = 2).  
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Figure 22. p53-EPSIN 3 regulates cell proliferation and apoptosis. 
At 24 h after transfection of each siRNA, HCT116 cells were seeded and cultured on ultra-
low attachment plates. At 24h after plating, HCT116 cells were treated with 1 μg/ml ADR for 
48 h and subjected to (A) cell proliferation analysis. Relative cell viability was calculated by 
dividing the absorbance of ADR-treated cells by that of untreated cells. Error bars represent 
S.D. (n = 3). (B) Western blot analysis was performed using HCT116 cells treated as the same 
as above. siRNA against EGFP was used as control.  
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Figure 23. Schematic of knockout vector design and PCR for mouse genotyping.  
(A) Numbered boxes refer to Epsin 3 exons. Arrows over and under DNA sequence 
indicate locations of primer for genotyping. (B) Result of PCR for mouse genotyping. The 
100bp ladder size marker was run in lane 1. Predicted sizes of PCR product from F1 and 
R for wild type allele is 398bps, and F2 and R for knockout allele is 621bps.   
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Figure 24. Confirmation of Epsin 3 knockout.  
(A) qPCR analysis of Epsin 3 expression in the thymus of X-ray-irradiated Epsin 3−/− or Epsin 3 
+/+ mice (10 Gy) (n=1 per group). β-actin was used for the normalization of expression levels. 
(B) Western blot analysis of Epsin 3 protein expression in the stomach of X-ray-irradiated 
Epsin 3−/− or Epsin 3 +/+ mice (10 Gy) (n=2-3per group). Red arrow indicates the protein band 
of Epsin 3. CBB staning was used for the loading control.  (C) Immunohistochemistry analysis 
of Epsin 3 protein expression in the stomach of X-ray-irradiated Epsin 3−/− or Epsin 3 +/+ mice 
(10 Gy). All mice were sacrificed 24 h after irradiation. 
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Figure 25. Survival and tumor development analysis of Epsin 3 wild-type and deficient 
mice.  
(A)Overall survival and (B) tumor-free survival curves of Epsin 3-/- (dashed lines) and  Epsin 
3+/+ (dashed lines) mice were plotted using Kaplan-Meier method. P-values were calculated 
by log-rank test.  Mice were irradiated 10Gy at day 0 and 4 Gy of X-ray weekly for 4 weeks. 
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Figure 26. Wound healing  experiment of Epsin 3 wild-type and deficient mice.  
Sequential change of the area of wounds created on the dorsa of Epsin 3-/- (dashed lines) 
and Epsin 3+/+ (dashed lines).   The area at each time-point was divided by the area at day 0.  
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Figure 27. Relation of EPSIN 3 expression  in cancer tissues. 
Using the data of RNA sequence in human colorectal cancer tissues obtained from The 
Cancer Genome Association (TCGA) database, gene expression analysis was performed. 
Box-plot indicates EPSIN 3 expression in colorectal tissues. The vertical axis indicates the 
normalized expression level of EPSIN 3, top bar represents maximum observation, lower bar 
represents minimum observation, top of the box is upper or third quartile, bottom of the 
box is lower or first quartile, middle bar is median value. P value was calculated by Mann-
Whitney U test.  
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Figure 28. Knockdown of CYSTATIN C expression by siRNA.  
HCT116 cells were transfected with small interference RNAs (siRNAs) against CYSTATIN C: 
siCystC-a and -b, 24 h prior to treatment with ADR. siEGFP was used as a control. At 48 h 
after treatment, total RNA and whole cell extracts were subjected to qPCR and 
immunoblot analysis, respectively. β-actin was used for normalization of expression levels 
in qRT-PCR analysis. Error bars represent S.D. (n = 3). 
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Figure 29. p53-CYSTATIN C regulates cell proliferation and apoptosis 
At 24 h after transfection of each siRNA, HCT116 cells were seeded and cultured on 
ultra-low attachment plates. At 24h after plating, HCT116 cells were treated with 1 
μg/ml ADR for 48 h and subjected to (A) cell proliferation analysis. Relative cell viability 
was calculated by dividing the absorbance of ADR-treated cells by that of untreated 
cells. Error bars represent S.D. (n = 3). (B) Western blot analysis was performed using 
HCT116 cells treated as the same as above. siRNA against EGFP was used as control.  
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Figure 30. Cathepsin L activity was regulated by p53-CYSTATIN C pathway. 
(A) HEK293T cells were transfected with CYSTATIN C expression plasmid or mock plasmid,  
(B) HCT116 p53+/+ or HCT116 p53-/- cells were treated with 2 μg/ml ADR for 2 h, or (C) 
HCT116 p53+/+ transfected with each siRNA were treated with 2 μg/ml ADR for 2 h. 
Cathepsin L activity was measured at 36 h after transfection or 48 h after ADR treatment. 
Error bars represent S.D. (n = 3). P- value was calculated by Student's t-test.  
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Figure 31. Relation of CYSTATIN C expression and p53 status in cancer tissues. 
Using the sequence data  of DNA and RNA in human cancer tissues obtained from TCGA 
database, gene expression analysis was performed. Box-plots indicate CYSTATIN C 
expression in (left) colorectal adenocarcinoma or (right) breast adenocarcinoma tissues. The 
vertical axis indicates the normalized expression level of CYSTATIN C, top bar represents 
maximum observation, lower bar represents minimum observation, top of the box is upper 
or third quartile, bottom of the box is lower or first quartile, middle bar is median value. P 
value was calculated by Mann-Whitney U test.  
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Figure 32. Prognostic effect of CYSTATIN C  
Survival analysis was performed using the sequence data of DNA and RNA, and clinical 
information that were obtained from TCGA database. Kaplan-Meier curves among (A and B) 
total breast adenocarcinoma patients. The patients were stratified into two groups 
according to (A) p53 mutation, or (B) CYSTATIN C expression (above or below median) in 
tumors tissues. P-values were calculated by log-rank test. 
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Table 1. Sequences of DNA and RNA oligonucleotides 66
Quantitative real-time PCR Forward Reverse
Human EPSIN 3 GAGAAGCTAAAAACCAGCCAGT CAGCAGAGCAGTGTGTGGA
Mouse Epsin 3 AAGGAGAGCCGGGACAGT TGCCATTCTGCTTGCAACT
Mouse Epsin 3 for confirmation of knockout CAAGACCAAAGAGCGAATGG CTCCAGGTCTGAGGCATAGC
Human CYSTATIN C ACTTCTTGGACGTGGAGCTG GCACAGCGTAGATCTGGAAA
Mouse cystatin C TGGTGAGAGCTCGTAAGCAG CCCATCTCCACATCCAAAAA
Gene repoter assay Forward Reverse
Human EPSIN 3 -p53BS CCGCTCGAGCTTCCACCCACCTCCCTTAG CCCAAGCTTGGATGATGTCAGGGGTAGGG
Human EPSIN 3 -p53BS1mut GGGTGTTGTCTGGGCCAGGTGGGGCT CAGAATACCTCTTTCCCGAGCAGCTTGGC
Human EPSIN 3 -p53BS2mut GGATAGTTTTTCTTTGGAAGACCCTACCC TGAATTACAGATTTTATGACTTTCTTGTC
mouse Epsin 3 -mp53BS1 TCCAGCAAAACACACAGCTC CCCCCTCTTTCTTTCACCTC
mouse Epsin 3 -mp53BS2 CCGCTCGAGAGCCGGACAGAAAGACAGAA CCCAAGCTTGCAAAAACTCCCCTTTCTCC
CYSTATIN C -p53BS CCGCTCGAGCTAGGACTAGCGGCCTTCAC CCCAAGCTTGTCTGTGTCACTGTTCGCTG
CYSTATIN C -p53BSmut GACTCTTCCTCTATCAGCTGATGCAGAGT AGGAATACTCCACCCCAGCAGGGACTCAG
ChIP assay Forward Reverse
Genomic fragment including p53BS2 （EPSIN 3 ） CCGTCCCAACAGCAAGAAG CCCAAGCTTGGATGATGTCAGGGGTAGGG
Genomic fragment including p53BS (CYSTATIN C ) CTTCGTGCGTCCCAATTTTA GTGTGTCTGTCCCTGGACTC
Expression vector Forward Reverse
EPSIN 3 AAAGAATTCTCTCCAGCCATGACGACCTC TTTCTCGAGGAGGAAGGGGTTGGTGCCGG
EPSIN 1 AAAGAATTCGGCACCATGTCGACCTCGTC TTTCTCGAGTAGGAGGAAGGGATTAGTG
CYSTATIN C AAAGAATTCCCGACCATGGCCGGGCCCCT TTTCTCGAGGGCGTCCTGACAGGTGGATT
Genotyping Forward Reverse
Mouse p53 GTTATGCATCCATACAGTACA CCGCAGGATTTACAGACACC
Mouse Epsin 3  wild-type GGCAACCAGCTCTGTAAAACAGAGG CCCTAGGTCACCCATTGTAAGAGGC
Mouse Epsin 3  knockout GGGATCTCATGCTGGAGTTCTTCG CCCTAGGTCACCCATTGTAAGAGGC
siRNA oligonucleotides Sense Antisense
siEPN3-a GCUCUAACAUUGCUGGACU AGUCCAGCAAUGUUAGAGC
siEPN3-b UCCAGACACUCAAGGACUU AAGUCCUUGAGUGUCUGGA
siEPN3-c GCACGUGUACAAGGCUCUA UAGAGCCUUGUACACGUGC
siEPN3-d CCUCGACCUUUGACCCAUU AAUGGGUCAAAGGUCGAGG
siCystC-a GGCACAAUGACCUUGUCGA UCGACAAGGUCAUUGUGCC 
siCystC-b GCACAAUGACCUUGUCGAA UUCGACAAGGUCAUUGUGC
siEGFP GCAGCACGACUUCUUCAAGTT CUUGAAGAAGUCGUGCUGCTT
sip53 GACUCCAGUGGUAAUCUACTT AGUAGAUUACCACUGGAGUCTT
67
Table 2. Prognostic factors in Cox’s proportional hazards model
Hazard ratio (95% CI) P -value Hazard ratio (95% CI) P -value
Expression of cystatin C Below median 1.656 (1.110 - 2.468) 0.0134 1.649 (1.054 -2.580) 0.0285
(vs. above median)
p53  status Mutant 1.560 (1.039 - 2.343) 0.0321 1.326 (0.838 - 2.098) 0.2277
(vs. wild-type )
Age ≥58 1.635 (1.094 - 2.445) 0.0166 1.877 (1.240 - 2.842) 0.0029
(vs. <58*)
Pathological stage II 1.283 (0.703 - 2.342) 0.4177 1.353 (0.739 - 2.476) 0.3275
(vs. stage I) III 2.212 (1.163 - 4.206) 0.0155 2.384 (1.252 - 4.540) 0.0082
IV 4.233 (1.823 - 9.825) 0.0008 4.008 (1.723 - 9.321) 0.0013
* Median age; CI, confidence interval
Univariate MultivariateVariables
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